ZBH

Business Context and Reporting Period

Company: Zimmer Holdings, Inc. (now Zimmer Biomet Holdings, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: July 23, 2003
Reporting Period: Second Quarter and Six Months ended June 30, 2003

Zimmer is a worldwide leader in reconstructive orthopaedic implants and trauma products. This filing reports strong operational results, the elimination of net debt, and the launch of a $3 billion acquisition offer for Centerpulse.

Key Financial Metrics

Half-Year (Six Months) Highlights:

• Net Sales: $801.2 million (+20.5% vs. prior year).
• Net Earnings: $224.3 million (+86.1% vs. prior year). Excluding the cumulative effect of a change in accounting principle, earnings increased 40%.
• Diluted EPS: $1.13 (+82.3% vs. prior year). Excluding accounting changes, EPS was $0.85 (+37.1%).
• Operating Cash Flow: $226.9 million for the six months.
• Free Cash Flow: $162.2 million for the six months.
• Debt Status: The company reported being "net debt free" as of June 30, 2003, having eliminated $450 million in net debt assumed at its spin-off.

Margins (Q2 2003):

• Gross Margin: 76.1%
• Operating Margin: 32.8%
• Net Margin: 21.7%
• EBITDA Margin: 38.1%

Material Changes vs. Prior Period

• Revenue Growth: Driven by strong performance in reconstructive implants (+22% Q2) and significant growth in the Europe region (+43% Q2). Americas sales grew 17%.
• Profitability: Operating profit grew 30.3% in Q2, outpacing revenue growth due to margin expansion and reduced interest expense (down 72.7% to $0.9 million).
• Accounting Change: A one-time cumulative effect of a change in accounting principle for surgical instruments (from expense-based to capitalization) added $55.1 million to net earnings for the six-month period.
• Balance Sheet: Cash and equivalents increased from $15.7 million (Dec 31, 2002) to $115.0 million (June 30, 2003). Short-term debt decreased from $156.7 million to $76.0 million.
• Acquisitions: Completed the purchase of the Immedica external fixation business and announced a $3 billion offer for Centerpulse.

Guidance, Outlook, and Risks

Full Year 2003 Guidance:

• Sales: Expected to grow approximately 18% to ~$1,620 million.
• Diluted EPS: Expected to grow approximately 29% to ~$1.69 (excluding acquisition costs and accounting adjustments).
• Quarterly Outlook: Q3 sales expected to grow ~16% to ~$390 million; Q4 sales expected to grow ~15% to ~$425 million.

Management Commentary: CEO Ray Elliott described the quarter as "landmark," citing leadership in Minimally Invasive Solutions (MIS), record margins, and debt elimination. The company was named a "Hot Growth" company by Business Week.

Risks and Contingencies:

• Acquisition Risks: The Centerpulse offer is subject to conditions and has not been agreed to by the target. Forward-looking statements regarding the acquisition are qualified by the lack of comprehensive due diligence.
• External Factors: Asia Pacific sales were negatively affected by the SARS epidemic (estimated $3 million impact in Q2), though recovery is expected.
• General Risks: Competition, technological changes, regulatory issues, reimbursement levels, and currency fluctuations.

Investor Verification Checklist

• Debt Elimination: Verify the specific mechanics of how the $450 million net debt was eliminated and the current status of the $76 million short-term debt.
• Accounting Change Impact: Review the reconciliation of the $55.1 million cumulative effect of the accounting change for surgical instruments to understand its impact on future depreciation and earnings.
• Centerpulse Acquisition: Monitor the status of the $3 billion offer, including regulatory approvals and the outcome of due diligence.
• EBITDA Reconciliation: Confirm the non-GAAP EBITDA figures against GAAP Operating Profit as disclosed in the earnings release (Exhibit 99(a)).
• SARS Recovery: Track Asia Pacific sales performance in subsequent quarters to confirm the expected recovery from the SARS-related revenue loss.